Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population

George Han, MD, PhD1; April W. Armstrong, MD, MPH2; Seemal R. Desai, MD3,4; Eric Guenin, PharmD, PhD, MPH5

1Icahn School of Medicine at Mount Sinai, New York, NY; 2Keck School of Medicine at University of Southern California, Los Angeles, CA; 3Innovative Dermatology, PA, Plano, TX; 4The University of Texas Southwestern Medical Center, Dallas, TX; 5Ortho Dermatologics, Bridgewater, NJ

SYNOPSIS
Acne is a common problem among Asian adolescents and adults.1,2 Generally, Asian skin is more pigmented, with a higher risk of acne compared to other ethnicities.3

The safety and efficacy of tretinoin 0.05% lotion was assessed in two phase 3 studies (NCT02932306, NCT02965456) for the treatment of moderate-to-severe acne in an Asian population.4,5

METHODS
Data from two phase 3 studies (NCT02932306, NCT02965456) were analyzed post hoc to evaluate the efficacy, tolerability, and safety of tretinoin 0.05% lotion in Asian participants with moderate-to-severe acne.

RESULTS
Participants
The pooled intent-to-treat analysis included 69 Asian participants, 42 (61.2%) of whom were female. The safety analysis was based on 69 Asian participants (56 evaluable/13 withdrawn).

Efficacy
At Week 12, mean percent reductions from baseline in inflammatory and noninflammatory lesion counts were greater with tretinoin 0.05% vs vehicle (Figure 1).

Safety
Only five Asian participants in the pooled population reported any AEs with tretinoin 0.05% lotion (Table 2). No treatment-related serious AEs and no concerns with skin dryness, irritation, or hyperpigmentation were reported.

CONCLUSIONS
Data pooled from two phase 3 studies showed that in Asian participants (n=69), tretinoin 0.05% lotion was more effective than vehicle in reducing inflammatory acne lesions and improving QoL.

REFERENCES

TABLE 2. Adverse Events

Summary of AEs, n (%)

Any AEs 64 (91.3) 26 (78.4)
Any AEs leading to discontinuation 5 (7.3) 1 (3.0)
Any serious AEs 0 0
Any AEs leading to withdrawal 0 0
Deaths 0 0

Summary of AEs, n (%)

AAE 1 (1.5) 0
Moderate 23 (34.8) 2 (5.9)
Severe 3 (4.4) 0

Any AEs leading to discontinuation 64 (91.3) 26 (78.4)
Any AEs leading to withdrawal 5 (7.3) 1 (3.0)
Deaths 0 0

Table 2: Summary of AEs, n (%)

AAE 1 (1.5) 0
Moderate 23 (34.8) 2 (5.9)
Severe 3 (4.4) 0

Any AEs leading to discontinuation 64 (91.3) 26 (78.4)
Any AEs leading to withdrawal 5 (7.3) 1 (3.0)
Deaths 0 0

AAE: Any Adverse Event; AEs: Adverse Events

ACKNOWLEDGEMENTS: Medical writing support was provided by Prescott Medical Communications Group (Chicago, IL) with financial support from Ortho Dermatologics | Presented at the Fall Clinical Dermatology Conference • October 17-20, 2019 • Las Vegas, NV